Todd Riehl

5.4k total citations
28 papers, 831 citations indexed

About

Todd Riehl is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Todd Riehl has authored 28 papers receiving a total of 831 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Todd Riehl's work include Lung Cancer Treatments and Mutations (15 papers), Cancer Genomics and Diagnostics (9 papers) and Colorectal Cancer Treatments and Studies (7 papers). Todd Riehl is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Cancer Genomics and Diagnostics (9 papers) and Colorectal Cancer Treatments and Studies (7 papers). Todd Riehl collaborates with scholars based in United States, United Kingdom and Switzerland. Todd Riehl's co-authors include Eric J. Sherman, Steven I. Sherman, Marcia S. Brose, Huibin Yue, Ezra E.W. Cohen, Maria E. Cabanillas, Lori J. Wirth, Igor Puzanov, David M. Hyman and Noopur Raje and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Todd Riehl

28 papers receiving 817 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Todd Riehl United States	13	431	288	284	196	185	28	831
Sharon B. Sams United States	17	514 1.2×	382 1.3×	208 0.7×	238 1.2×	229 1.2×	40	1.0k
Amy Prawira Canada	11	326 0.8×	172 0.6×	147 0.5×	134 0.7×	111 0.6×	38	621
Brianne Kaiser United States	4	227 0.5×	405 1.4×	132 0.5×	96 0.5×	97 0.5×	4	607
Sarah M. Nielsen United States	16	273 0.6×	255 0.9×	147 0.5×	85 0.4×	340 1.8×	75	882
Hidenori Mizugaki Japan	14	400 0.9×	207 0.7×	231 0.8×	64 0.3×	92 0.5×	40	710
Jaymes Holland United States	14	259 0.6×	294 1.0×	299 1.1×	71 0.4×	143 0.8×	25	769
Ulla Johansson Sweden	16	598 1.4×	272 0.9×	200 0.7×	68 0.3×	493 2.7×	21	1.1k
Constantijne H. Mom Netherlands	17	425 1.0×	397 1.4×	221 0.8×	63 0.3×	153 0.8×	57	1.1k
Daria Arbogast United States	9	483 1.1×	385 1.3×	149 0.5×	674 3.4×	79 0.4×	9	1.2k
Ciara C. O’Sullivan United States	18	590 1.4×	293 1.0×	262 0.9×	38 0.2×	299 1.6×	72	1.0k

Countries citing papers authored by Todd Riehl

Since Specialization

Citations

This map shows the geographic impact of Todd Riehl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd Riehl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd Riehl more than expected).

Fields of papers citing papers by Todd Riehl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd Riehl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd Riehl. The network helps show where Todd Riehl may publish in the future.

Co-authorship network of co-authors of Todd Riehl

This figure shows the co-authorship network connecting the top 25 collaborators of Todd Riehl. A scholar is included among the top collaborators of Todd Riehl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd Riehl. Todd Riehl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Doebele, Robert C., Huong Trinh, Reynaldo Martina, et al.. (2021). Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data inROS1+ NSCLC. Journal of Comparative Effectiveness Research. 10(17). 1271–1282. 14 indexed citations

Dziadziuszko, Rafał, Fabrice André, Wesley Yip, et al.. (2020). 1193P Clinical validity of FoundationOne liquid CDx (F1L CDx) assay as an aid in selecting patients for treatment with entrectinib. Annals of Oncology. 31. S785–S786. 4 indexed citations

Subbiah, Vivek, Igor Puzanov, Jean‐Yves Blay, et al.. (2020). Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers. Cancer Discovery. 10(5). 657–663. 86 indexed citations

Zhang, Weijiang, Christine McIntyre, Todd Riehl, et al.. (2020). Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAF^V600 Mutation–Positive Malignancies. Clinical Pharmacology in Drug Development. 9(5). 651–658. 3 indexed citations

Doebele, Robert C., Huong Trinh, Reynaldo Martina, et al.. (2019). P1.01-83 Comparative Efficacy Analysis Between Entrectinib Trial and Crizotinib Real-World ROS1 Fusion-Positive (ROS1+) NSCLC Patients. Journal of Thoracic Oncology. 14(10). S392–S392. 5 indexed citations

Verweij, Jaap, Hans R. Hendriks, H. Zwierzina, et al.. (2019). Innovation in oncology clinical trial design. Cancer Treatment Reviews. 74. 15–20. 39 indexed citations

Gadgeel, Shirish M., Tony Mok, Solange Peters, et al.. (2019). Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort. Annals of Oncology. 30. v918–v918. 27 indexed citations

Subbiah, Vivek, Radj Gervais, Gregory J. Riely, et al.. (2019). Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology. 1–9. 57 indexed citations

Doebele, Robert C., Huong Trinh, Reynaldo Martina, et al.. (2019). Time-to-treatment discontinuation (TTD) and real-world progression-free survival (rwPFS) as endpoints for comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients.. Journal of Clinical Oncology. 37(15_suppl). 9070–9070. 3 indexed citations

10.

Doebele, Robert C., Myung‐Ju Ahn, Salvatore Siena, et al.. (2018). OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 13(10). S321–S322. 36 indexed citations

11.

Lu, Michael W., Natalia Sadetsky, Peter Lambert, et al.. (2018). Real-world data (RWD) on tumor response (rwTR) in advanced non-small cell lung cancer (aNSCLC) patients receiving cancer immunotherapy and targeted therapies.. Journal of Clinical Oncology. 36(15_suppl). 6578–6578. 1 indexed citations

12.

Zhang, Weijiang, Christine McIntyre, Rabab Gaafar, et al.. (2018). Effect of Rifampicin on the Pharmacokinetics of a Single Dose of Vemurafenib in Patients With BRAF^V600 Mutation–Positive Metastatic Malignancy. Clinical Pharmacology in Drug Development. 8(6). 837–843. 6 indexed citations

13.

Rittmeyer, Achim, David R. Gandara, Marcin Kowanetz, et al.. (2018). Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK). Pneumologie. 72(S 01). S49–S50. 11 indexed citations

14.

Cohn, Allen Lee, et al.. (2017). <em>BRAF</em><sup>V600</sup> mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study. OncoTargets and Therapy. Volume 10. 965–971. 27 indexed citations

15.

Mok, Tony, Shirish M. Gadgeel, Vamsidhar Velcheti, et al.. (2017). Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC. Annals of Oncology. 28. v494–v495. 12 indexed citations

16.

Gandara, David R., Marcin Kowanetz, Tony Mok, et al.. (2017). Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK). Annals of Oncology. 28. v460–v460. 62 indexed citations

17.

Hyman, David M., Thomas Kaley, Antoine Hollebecque, et al.. (2017). Vemurafenib in patients with BRAF^V600 mutant glioma: A cohort of the histology-independent VE-basket study.. Journal of Clinical Oncology. 35(15_suppl). 2004–2004. 1 indexed citations

18.

Mok, Tony, Rafał Dziadziuszko, Solange Peters, et al.. (2017). P1.04-011 Development of Novel Blood-Based Biomarker Assays in 1L Advanced/Metastatic NSCLC: Blood First Assay Screening Trial (BFAST). Journal of Thoracic Oncology. 12(11). S1976–S1976. 1 indexed citations

19.

Brose, Marcia S., Maria E. Cabanillas, Ezra E.W. Cohen, et al.. (2016). Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. The Lancet Oncology. 17(9). 1272–1282. 271 indexed citations

20.

Möller, Hans‐Jürgen, et al.. (1991). Efficacy and Tolerability of a New Antipsychotic Compound (Risperidone): Results of a Pilot Study. Pharmacopsychiatry. 24(6). 185–189. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact